DUBLIN – Chicago Cubs fans excepted, 2016 was a bad year for many for a whole host of reasons. The travails of the Australian cell therapy developer Mesoblast Ltd. may not have registered broadly, but the firm had a torrid year.
DUBLIN – Chicago Cubs fans excepted, 2016 has been a bad year for many for a whole host of reasons. The travails of the Australian cell therapy developer Mesoblast Ltd. may not have registered broadly, but the firm has had a torrid year.
PERTH, Australia – Drug and device companies in Australia may soon be able to bring their products to market more quickly via a new priority review designation.
PERTH, Australia – The Australian government is making good on its promise to invest in innovation with Prime Minister Malcolm Turnbull announcing nearly A$1 billion (US$744.6 million) in new grants and funds to build stronger national networks in translational science.
PERTH, Australia – The Australian government is making good on its promise to invest in innovation with Prime Minister Malcolm Turnball announcing nearly A$1 billion (US$744.6 million) in new grants and funds to build stronger national networks in translational science.
PERTH, Australia – Drug and device companies in Australia may soon be able to bring their products to market more quickly via a new priority review designation. Health Minister Susan Ley introduced legislation to Parliament on Dec. 1 that would speed the approval of drugs and devices by providing Australia's Therapeutic Goods Administration (TGA) with new priority review mechanisms. TGA spokeswoman Kay McNiece told Medical Device Daily that the bill is the first tranche of legislation to support the recommendations of the Expert Panel Review of Medicines and Medical Devices Regulation, as agreed by the...
PERTH, Australia – Drug and device companies in Australia may soon be able to bring their products to market more quickly via a new priority review designation. Health Minister Susan Ley introduced legislation to Parliament on Dec. 1 that would speed the approval of drugs and devices by providing Australia's Therapeutic Goods Administration (TGA) with new priority review mechanisms.
PERTH, Australia – Drug and device companies in Australia may soon be able to bring their products to market more quickly via a new priority review designation.
